[go: up one dir, main page]

PE20150965A1 - Azaindolinas - Google Patents

Azaindolinas

Info

Publication number
PE20150965A1
PE20150965A1 PE2015000475A PE2015000475A PE20150965A1 PE 20150965 A1 PE20150965 A1 PE 20150965A1 PE 2015000475 A PE2015000475 A PE 2015000475A PE 2015000475 A PE2015000475 A PE 2015000475A PE 20150965 A1 PE20150965 A1 PE 20150965A1
Authority
PE
Peru
Prior art keywords
compounds
pyrrolo
methylamino
dihydro
acetyl
Prior art date
Application number
PE2015000475A
Other languages
English (en)
Inventor
Joan Heather Hogg
Robert Francis Kester
Weiling Liang
Weiya Yun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20150965A1 publication Critical patent/PE20150965A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invencion describe compuestos de formula l o sales farmaceuticamente aceptables del mismo, en el que W, Y, Z, R1, R2, R3 y R4 son como se describe en esta solicitud, y metodos para usar los compuestos en el tratamiento del cancer. Los compuestos preferidos son: etilamida del acido (R,S)-1-[(S)-2-ciclohexil-2-((S)-2-metilamino-propionilamino)-acetil]-2,3-dihidro-1H-pirrolo[2,3-b]piridin-2-carboxilico, etilamida del acido (R,S)-1-[(S)-2-ciclohexil-2-((S)-2-metilamino-butirilamino)acetil]-2,3-dihidro-1H-pirrolo[2,3-b]piridin-2-carboxilico, entre otros
PE2015000475A 2012-10-11 2013-10-08 Azaindolinas PE20150965A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261712305P 2012-10-11 2012-10-11

Publications (1)

Publication Number Publication Date
PE20150965A1 true PE20150965A1 (es) 2015-06-20

Family

ID=49304982

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000475A PE20150965A1 (es) 2012-10-11 2013-10-08 Azaindolinas

Country Status (18)

Country Link
US (1) US9309248B2 (es)
EP (1) EP2906559B1 (es)
JP (1) JP6333826B2 (es)
KR (1) KR20150067182A (es)
CN (1) CN104540825B (es)
AU (1) AU2013328870A1 (es)
CA (1) CA2880324A1 (es)
CL (1) CL2015000886A1 (es)
CR (1) CR20150148A (es)
EA (1) EA201590656A1 (es)
ES (1) ES2623304T3 (es)
IL (1) IL237115A (es)
MA (1) MA38009B1 (es)
MX (1) MX2015004525A (es)
PE (1) PE20150965A1 (es)
PH (1) PH12015500399A1 (es)
SG (1) SG11201501314TA (es)
WO (1) WO2014056871A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
ES2901829T3 (es) * 2017-07-06 2022-03-23 Janssen Pharmaceutica Nv Derivados de azaindolina sustituida como inhibidores de NIK
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118985A1 (en) * 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
EP1392289A2 (en) 2001-05-23 2004-03-03 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
BRPI0513310A (pt) 2004-07-12 2008-05-06 Idun Pharmaceuticals Inc análogos de tetrapeptìdeo
JP2009501187A (ja) 2005-07-15 2009-01-15 エフ．ホフマン−ラ ロシュ アーゲー 新規なヘテロアリール縮合環式アミン
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
EP2318395A4 (en) * 2008-08-02 2011-10-26 Genentech Inc IPA INHIBITORS
MX2011006509A (es) * 2008-12-19 2011-10-19 Genentech Inc Compuestos heterociclicos y métodos de uso.
WO2011059763A2 (en) * 2009-10-28 2011-05-19 Joyant Pharmaceuticals, Inc. Dimeric smac mimetics
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
KR20150064736A (ko) * 2012-10-11 2015-06-11 에프. 호프만-라 로슈 아게 아자인돌린

Also Published As

Publication number Publication date
JP6333826B2 (ja) 2018-05-30
ES2623304T3 (es) 2017-07-10
CN104540825B (zh) 2017-10-24
AU2013328870A1 (en) 2015-02-26
MX2015004525A (es) 2015-07-06
PH12015500399A1 (en) 2015-04-27
CL2015000886A1 (es) 2015-07-17
CA2880324A1 (en) 2014-04-17
IL237115A (en) 2016-12-29
US9309248B2 (en) 2016-04-12
EP2906559B1 (en) 2017-02-08
US20150266879A1 (en) 2015-09-24
EA201590656A1 (ru) 2015-07-30
JP2015534570A (ja) 2015-12-03
KR20150067182A (ko) 2015-06-17
MA38009A1 (fr) 2018-02-28
MA38009B1 (fr) 2018-09-28
CR20150148A (es) 2015-04-30
WO2014056871A1 (en) 2014-04-17
EP2906559A1 (en) 2015-08-19
CN104540825A (zh) 2015-04-22
HK1206738A1 (en) 2016-01-15
SG11201501314TA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
CL2012002270A1 (es) Compuestos derivados de pirrolo[2,3-d]-pirimidina composición farmacéutica que los comprende; utiles en el tratamiento del cancer.
CL2008001745A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer.
MX2012004157A (es) 8-etil-6-(aril)pirido[2.3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del snc.
CL2014001752A1 (es) Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras.
GT201400213A (es) Inhibidores de diacilglicerol aciltransferasa 2
CL2009001212A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de cinasas; composicion farmaceutica que los comprende; y su uso en el tratamiento de demencia vascular, trastorno del snc, cancer, entre otras.
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
CR20110216A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
PE20170128A1 (es) Compuestos para tratar atrofia muscular espinal
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
CL2009000724A1 (es) Compuestos derivados de 1,2,3,4-tetrahidro-pirido[3,4-b]indol, moduladores del receptor de histamina, serotonina y dopamina; composicion farmaceutica; kit farmaceutico; y uso para tratar un trastorno cognitivo, psicotico, mediado por neurotransmisores y/o neurologico.
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
UY35142A (es) Derivados de triazolopirazinas como inhibidores de brd4
ES2636936T3 (es) Derivados de triazolo[4,5-d]pirimidina para el tratamiento de enfermedades tales como cáncer
ECSP14013215A (es) Compuestos novedosos
CL2009000957A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina; inhibidores de limk2; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos inflamatorios, glaucoma, neurodegeneracion, entre otras.
AR077144A1 (es) Derivado de fenilimidazol como inhibidor de la enzima pde10a, composiciones farmaceuticas y uso de los mismos en el tratamiento de trastornos neurodegenerativos y psiquiatricos
DOP2011000153A (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para el uso en el trata miento del cancer
CO6491087A2 (es) Compuestos de urea que contienen heteroarilo 5,6 bicíclicos como inhibidores de quinasa
CO7091174A2 (es) Compuestos triazolo como inhibidores de pde10
MX340574B (es) Imidazo pirazinas.

Legal Events

Date Code Title Description
FD Application declared void or lapsed